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Summary
Background Primary Sjögren’s syndrome is an autoimmune disease that presents as dryness of the mouth and eyes 
due to impairment of the exocrine glands. To our knowledge, no systemic therapies for primary Sjögren’s syndrome 
have shown efficacy. CD40–CD154-mediated T cell–B cell interactions in primary Sjögren’s syndrome contribute to 
aberrant lymphocyte activation in inflamed tissue, leading to sialadenitis and other tissue injury. Therefore, we 
investigated the safety and preliminary efficacy of iscalimab (CFZ533), a novel anti-CD40 monoclonal antibody, in 
patients with primary Sjögren’s syndrome.
Methods This multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study took place at ten 
investigational sites across Europe (UK, n=4; Germany, Switzerland, and Hungary, n=1 each) and the USA (n=3). Eligible 
patients were aged 18–75 years and fulfilled the 2002 American European consensus group diagnostic classification 
criteria for primary Sjögren’s syndrome. In the double-blind phase of the trial, patients were randomly assigned (2:1) via 
computer-generated unique randomisation numbers to receive subcutaneous iscalimab (3 mg/kg) or placebo at weeks 0, 
2, 4, and 8 (cohort 1) or intravenous iscalimab (10 mg/kg) or placebo at weeks 0, 2, 4, and 8 (cohort 2). Randomisation was 
stratified according to baseline intake of oral corticosteroids. At week 12, patients in both cohorts received open-label 
iscalimab (same dose and route) for 12 weeks. The primary objectives of the study were to assess the safety, tolerability, and 
efficacy of multiple doses of iscalimab in the two sequential dose cohorts. Safety and tolerability were assessed by adverse 
events and efficacy of iscalimab versus placebo was assessed by clinical disease activity, as measured by the change in 
European League Against Rheumatism Sjögren’s syndrome disease activity index (ESSDAI) score after 12 weeks of 
treatment. Analyses were done on a per-protocol basis. The trial was registered with ClinicalTrials.gov, NCT02291029.
Findings Between Oct 22, 2014, and June 28, 2016, we assessed 82 patients for eligibility (25 for cohort 1 and 57 for 
cohort 2). 38 patients were excluded because of ineligibility. In cohort 1, 12 patients were randomly assigned to receive 
either 3 mg/kg doses of iscalimab (n=8) or placebo (n=4), and in cohort 2, 32 patients were randomly assigned to 
receive either intravenous 10 mg/kg doses of iscalimab (n=21) or placebo (n=11). Adverse events were similar between 
iscalimab treatment groups and placebo groups, with adverse events occurring in all patients in cohort 1, and in 
52% and 64% of the iscalimab and placebo groups, respectively, in cohort 2. Two serious adverse events were reported 
(one case of bacterial conjunctivitis in cohort 1 and one case of atrial fibrillation in cohort 2), which were unrelated to 
treatment with iscalimab. Intravenous treatment with iscalimab resulted in a mean reduction of 5·21 points (95% CI 
0·96–9·46; one-sided p=0·0090) in ESSDAI score compared with placebo. There was no signficiant difference in 
ESSDAI score between subcutaneous iscalimab and placebo.
Interpretation To our knowledge, this is the first randomised, placebo-controlled proof-of-concept study of a new 
investigational drug for primary Sjögren’s syndrome that indicates preliminary efficacy. Our data suggest a role of 
CD40–CD154 interactions in primary Sjögren’s syndrome pathology and the therapeutic potential for CD40 blockade 
in this disease should be investigated further.
Funding Novartis Pharma.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Introduction
Primary Sjögren’s syndrome is a systemic autoimmune 
disease characterised by progressive multiorgan immune-
mediated dysfunction that mainly affects exocrine glands, 
typically lacrimal and salivary glands. This dysfunction 
leads to oral and ocular dryness, excessive fatigue, 
extra glandular manifestations, and an increased risk of 
lymph oma.1 Treatment is limited to symptomatic care for 
dryness and muscosal symptoms. Disease-modifying 
therapies are used for some extraglandular manifestations 
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but can lead to adverse effects on the lungs, kidneys, 
and joints. There is no evidence-based, systemic disease-
modifying therapy approved for primary Sjögren’s 
syndrome.
Hallmark clinical features include the presence of 
anti-Sjögren’s-syndrome-related antigen A (anti-Ro/SSA), 
with or without anti-Sjögren’s-syndrome-related antigen 
B (anti-La/SSB),2 and focal lymphocytic sialadenitis on 
labial salivary glands or parotid biopsies. Ectopic lymph-
oid structures resembling germinal centres have also 
been observed within salivary glands from patients with 
prim ary Sjögren’s syndrome,3 and have been rep orted 
to be col o cal ised with expression of the B cell-attracting 
chemo kine CXCL13.4 The presence of salivary gland 
ectopic lymphoid stuctures5 and increased systemic 
levels of CXCL136 correl ate with disease severity, impli-
cating ecto pic lymphoid structures and accompany -
ing B-cell hyper reactivity in the pathology of primary 
Sjögren’s syndrome.7
B-cell activation, immunoglobulin class-switching, and 
germinal centre formation are regulated by various imm-
uno logical costimulatory pathways, notably CD40–CD154 
inter actions.8,9 Previous findings on the express ion of 
CD154 on salivary gland-infiltrating T cells and 
CD40 on salivary gland-infiltrating B cells10,11 suggest 
that T cell–B cell interactions via this pathway might 
con tribute to sialadenitis and ectopic lymphoid struc-
ture formation and function. Furthermore, data suggest 
that activated CD154-expressing T cells could facili-
tate the destruction of salivary gland epithelial cells 
that express CD40, potentially affecting salivary gland 
function.12,13 Inhibition or blocking of the CD40 pathway 
in mouse models of Sjögren’s syndrome suppresses 
sialadenitis.14,15
Collectively, these data suggest CD40–CD154 interactions 
might be involved in the pathology of primary Sjögren’s 
syndrome; however, to our knowledge, no clinical evidence 
supports a pivotal role for this pathway in primary 
Sjögren’s syndrome. If this costimulatory path way were to 
be involved, blockade in patients with clinically active 
primary Sjögren’s syndrome might pro vide thera peutic 
benefit. Therefore, the aim of this double-blind, placebo-
controlled proof-of-concept study was to assess the effects 
of iscalimab (CFZ533),16 a novel antagonistic and non-
depleting, anti-CD40 monoclonal antibody, in patients 
with primary Sjögren’s syndrome.
Research in context
Evidence before this study
We searched PubMed, with no language restrictions, between 
Oct 15, and Oct 21, 2018, and then again between May 15, and 
May 30, 2019 using the keywords “Sjögren’s syndrome”, “clinical 
trial”, “CD40”, “pathology”, “germinal center”, and “CXCL13”, to 
identify studies on the pathophysiology and treatment of primary 
Sjögren’s syndrome. A small number of randomised controlled 
trials have tested various treatment modalities in primary 
Sjögren’s syndrome, but none of these showed convincing 
efficacy. A published meta-analysis of 32 trials that evaluated 
19 different medications for primary Sjögren’s syndrome revealed 
that none of these showed consistent benefit in xerostomia and 
keratoconjunctivitis sicca. Previously published results suggest an 
association between primary Sjögren’s syndrome and 
CD40–CD154 interactions. For example, ectopic lymphoid 
structure formation alongside CD40 and CD154 expression in 
salivary gland biopsies from patients with primary Sjögren’s 
syndrome has been reported. Furthermore, amelioration of 
sialadenitis and reductions in anti-Sjögren’s-syndrome-related 
antigen A and anti-Sjögren’s-syndrome-related antigen B 
autoantibodies have been observed in the non-obese diabetic 
mouse model of Sjögren’s syndrome after CD40–CD154 blockade. 
Although an association between the CD40–CD154 pathway and 
autoimmune diseases such as primary Sjögren’s syndrome has 
been suggested, no clinical trial has assessed the efficacy and 
safety of any modality that blocks this pathway in patients with 
primary Sjögren’s syndrome.
Added value of this study
We ran a randomised, placebo-controlled proof-of-concept 
study with iscalimab in patients with clinically active primary 
Sjögren’s syndrome, using the European League Against 
Rheumatism Sjögren’s Syndrome Disease Activity Index 
(ESSDAI) to define disease activity (ESSDAI ≥6, reflecting the 
systemic manifestations of the disease) for both inclusion of 
patients and one primary endpoint. This established and 
validated composite outcome measure is regarded as an 
acceptable regulatory endpoint for pivotal clinical trials, and 
has been previously used in other primary Sjögren’s syndrome 
clinical trials. Iscalimab is a fully-human, pathway-blocking, 
non-depleting, anti-CD40 antibody. Iscamilab was well-tolerated 
in patients with primary Sjögren’s syndrome and, to our 
knowledge, this drug treatment is the first to result in a clinically 
meaningful change in systemic complications of the disease as 
measured by ESSDAI. These findings suggest CD40–CD154 
interactions are associated with primary Sjögren’s syndrome 
pathology and indicate beneficial effects of CD40 blockade in 
this disease. Our trial is the first randomised clinical trial for an 
investigational drug in primary Sjögren’s syndrome to show 
clinically meaningful efficacy using the recently established 
ESSDAI outcome measure.
Implications of all the available evidence
Our preliminary findings suggest a role of CD40–CD154 
interactions in primary Sjögren’s syndrome pathology and add to 
the evidence that this novel anti-CD40 antibody deserves further 
research into whether it can deliver clinically meaningful benefit 
in patients with primary Sjögren’s syndrome in longer trials with 
more patients.
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Methods 
Study design and participants
This exploratory, multicentre, randomised, double-blind, 
placebo-controlled, parallel-group, proof-of-concept study 
aimed to asses the safety, tolerability, efficacy, and pharma-
cokinetics of iscalimab (CFZ533) in patients with prim-
ary Sjögren’s syndrome. The study took place at ten 
inves ti gational sites (University Hospitals Birmingham 
NHS Foundation Trust, Birmingham, UK; University of 
Debrecen, Debrecen, Hungary; Newcastle upon Tyne 
Hospitals NHS Foundation Trust, Newcastle upon Tyne, 
UK; William Harvey Research Institute, Queen Mary 
University of London, Barts Health NHS Trust, London, 
UK; Charité Research Organisation, Berlin, Germany; 
Tufts University, Meford, MA, USA; University Hospital 
Basel, Basel, Switzerland; Altoona Center for Clinical 
Research, Duncansville, PA, USA; Rheumatology, Allergy 
and Immunology NYU Winthrop Hospital, Mineola, NY, 
USA; and University College Hospital, London, UK).
Eligible patients were aged 18–75 years, weighed 
50–150 kg, and fulfilled the 2002 American European 
consensus group diagnostic classification criteria for prim-
ary Sjögren’s syndrome.17 Patients had at least moderate 
systemic disease activity with a European League Against 
Rheumatism (EULAR) Sjögren’s syndrome disease activity 
index (ESSDAI) of 6 or greater18,19 and a stimu lated whole 
salivary flow rate greater than 0 mL/min. Only autoanti-
body seropositive patients were enrolled, defined by the 
presence of either anti-SSA antibodies or elevated serum 
titres of both antinuclear antibody (≥1:160) and positive 
rheumatoid factor.
Eligible patients could remain on a stable dose of 
standard-of-care treatment, such as hydroxychloro quine, 
or low-dose immunosuppressives (including metho-
trexate, azathioprine, or corticosteroids up to 10 mg 
per day [equi valent to prednisolone]). Women of child-
bearing potential were required to use highly effective 
contraception and were assessed by pregnancy test 
through out the study. Complete eligibility criteria are 
listed in the protocol. 
Exclusion criteria included treatment with biological 
therapies or strong immunosuppressives (eg, cyclo-
phosphamide or rituximab) within the 6 months before 
enrolment, infection, malignancy, secondary Sjögren’s 
syndrome, or any clinically significant and uncontrolled 
concurrent medical condition (eg, presence of lupus 
anti coagulant, hypertension, or psychiatric conditions). 
Patients with clinically significant labor atory abnormal-
ities (eg, total white blood cell count out side the range 
of 2·0–15·0 × 10⁹/L, platelets <100 × 10⁹/L, haemoglobin 
<9·0 g/dL, lymphocyte count <0·8 × 10⁹/L, neutrophil 
count <1·5 × 10⁹/L, or liver abnormalities at screening) 
were not eligible for inclusion. Complete exclusion 
criteria are listed in the study protocol.
Patients with primary Sjögren’s syndrome at each study 
site were provided with written information detailing the 
study and the study was also described by the investigator. 
Patients who met the eligibility criteria were then recruited 
after obtaining written informed consent. Con sent was 
obtained from patients before any assessment. Study 
site health authorities and review boards approved the 
study protocol.
Randomisation and masking
Patients were randomly assigned (2:1) to receive either 
active drug treatment or placebo to assess the safety, 
tolerability, pharmacokinetics, and preliminary clinical 
efficacy of multiple subcutaneous (cohort 1) or intravenous 
(cohort 2) doses of iscalimab. Patients were assigned 
computer-generated unique randomisation numbers in 
ascending, sequential order within cohorts to ensure 
treatment assignment was unbiased and concealed from 
patients and investigator staff. Randomisation was strati -
fied according to baseline intake of oral cortico steroids. 
A randomisation list per cohort automated the assign -
 ment of treatment group to randomisation numbers in 
the specified ratio. An unmasked pharma cist’s sole role 
was to ensure patients received the correct medica tion. 
All treat ment drugs were identical to ensure treatment 
identities were concealed.
Procedures
Iscalimab (150 mg lyophilisate) and matching placebo 
were prepared by Novartis (Basel, Switzerland) and 
supplied to the investigator site as open-label bulk 
medication. Both cohorts had a 12-week double-blind, 
placebo-controlled period, followed by a 12-week open-
label period where all patients received iscalimab, and 
then an 8-week follow-up (figure 1). In the double-blind 
period of cohort 1, patients received either 3 mg/kg 
doses of iscalimab or placebo via sub cutatneous injec-
tions at a 2:1 ratio at weeks 0, 2, 4, and 8. In the double-
blind period of cohort 2, patients received either 
intra venous 10 mg/kg doses of iscalimab or placebo at a 
For the study protocol see 
https://www.clinicaltrials.gov/
ProvidedDocs/29/
NCT02291029/Prot_000.pdf
Figure 1: Clinical study design
Each cohort was done sequentially. Treatment regimens were as follows: cohort 1, 3 mg/kg subcutaneous iscalimab 
(or placebo) at weeks 0, 2, 4, and 8 followed by 3 mg/kg subcutaneous iscalimab at weeks 12, 14, 16, and 20; 
cohort 2, 10 mg/kg intravenous iscalimab (or placebo) at weeks 0, 2, 4, and 8 followed by 10 mg/kg intrvenous 
iscalimab at weeks 12, 14, 16, and 20.
Week –4 Week 0 Week 4 Week 8 Week 12 Week 16 Week 20 Week 24 Week 32
Cohort 2
End of study
Cohort 1
Screening
baseline
Double-blind 
placebo-controlled period 1 
Open-label (all iscalimab) 
period 2 
Safety follow-up
 
Placebo
Iscalimab 10 mg/kg intravenous
Iscalimab 10 mg/kg intravenous
Iscalimab 10 mg/kg intravenous
Placebo
Iscalimab 3 mg/kg 
subcutaneous
Iscalimab 3 mg/kg 
subcutaneous
Iscalimab 3 mg/kg 
subcutaneous
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2:1 ratio. The cohort 2 study design was identical to 
cohort 1.
After the double-blind phase, patients entered an open-
label period in which they received their respective active 
treatment (iscalimab) doses at weeks 12, 14, 16, and 20. All 
patients were assessed at the end of the open-label period 
(week 24) and then entered an 8-week follow-up period 
and were assessed at weeks 28 and 32.
During treatment and follow-up periods, pharma-
cokinetic data were collected to characterise the disposition 
of iscalimab under saturating or non-saturating conditions 
and the contribution of CD40 receptors to the elimi-
nation of iscalimab. Iscalimab displays target-mediated 
disposition, which is a process in which a substantial 
proportion of the drug (relative to dose) is bound to its 
target, affecting the disposition of the drug. Iscalimab 
binds to CD40 receptors on the cell surface, which triggers 
internalisation16 and subsequent lysosomal degradation of 
the complex.
After completion of the initially planned cohorts, the 
study was amended to include a third open-label cohort, 
with the primary objective of assessing the effect of 
iscalimab dosing regimens on pharmacokinetic pro-
perties, the results of which will be presented elsewhere.
To evaluate the efficacy of iscalimab, we used the 
follow ing disease-relevant outcome measures to record 
changes in physician and patient clinical assessments: 
ESSDAI, a validated systemic disease activity index used 
to standarise assessments of systemic complications in 
clinical trials,18,20 and EULAR Sjögren’s syndrome patient 
reported index (ESSPRI). ESSDAI score is derived from 
the total weighted scores of 12 organ-specific domains 
that contribute to disease activity, with each being scored 
in four levels according to severity, and the ESSPRI score 
is derived from the mean scores of three symptoms—
dryness, limb pain, and fatigue.
We determined free iscalimab plasma concentrations 
by a standard validated enzyme-linked immunosorbent 
assay using biotinylated recombinant CD40 bound to 
streptavidin-coated microtitre plates and detected by a 
peroxidase-conjugated goat anti-human IgG antibody.
We determined presence of anti-iscalimab antibodies 
in plasma with a validated bridging ELISA-based assay. 
In a pre-incubation step, we used biotinylated iscalimab 
for capture and digoxigenin-labelled iscalimab and Fab 
fragments of a polyclonal anti-digoxigenin antibody conju-
gated to horseradish peroxidase for detection. 250 ng/mL 
of rabbit polyclonal affinity purified anti-CFZ533 IgG 
(positive control) could be detected in the presence of up 
to 20·2 μg/mL of iscalimab and 500 ng/mL of the positive 
control could be detected in the presence of up to 
45·0 μg/mL of iscalimab. We used a three-tiered strategy 
for immunogenicity testing with a screening assay, a con-
firmatory assay, and a titre assay.
CXCL13 was measured in cohort 2 using a validated 
bead-based sandwich immunoassay (R&D Systems; 
Minneapolis, MN, USA). The dynamic range, defined by 
the lower limit of quantification and upper limit of 
quantification, was 32·6–2760 pg/mL in human serum.
We measured serum anti-SSB, anti-SSA 52, and anti-
SSA 60 IgG with validated individual commercial in vitro 
diagnostic medical device kits from Orgentec (Mainz, 
Germany). The dynamic ranges defined by the lower limit 
of quantification and upper limit of quantification were 
1250–100 000 U/mL in human serum, accounting for the 
minimal dilution requirement of 1:500 for anti-SSB and 
anti-SSA 52 IgG, and 2500–200 000 U/mL in human 
serum, accounting for the minimal dilution requirment of 
1:1000 for anti-SSA 60 IgG.
Outcomes
The primary objectives of the study were to assess 
the safety, tolerability, and efficacy of multiple doses of 
iscalimab in the two sequential dose cohorts. The trial was 
initiated to evaluate the 3 mg/kg subcutaneous dose. Once 
supportive data for higher dose levels became available 
from the completed phase 1 first-in-human trial of 
iscalimab,22 the clinical study protocol was amended to 
include an additional cohort to assess the safety, tolerability, 
and efficacy of multiple doses of 10 mg/kg intravenous 
iscalimab. Safety and tolerability were measured by adverse 
events, and efficacy was assessed by comparing the effect 
of intravenous infusions of iscalimab versus placebo on 
the clinical disease activity of patients with primary 
Sjogren’s syndrome by the change in ESSDAI score after 
12 weeks of treatment.
Secondary outcome measures were pharmacokinetic 
assessment of multiple subcutaneous and intravenous 
doses of iscalimab. Self-reported out comes in patients 
were evaluated after 12 weeks, measured by ESSPRI, the 
36-item short form (SF-36) health survey of QoL measures, 
the multidimensional fatigue inventory (MFI) 20-item 
patient-reported questionnaire designed to meas ure forms 
of fatigue, and a visual analog scale (VAS) that recorded 
changes in physician and patient global assessment of the 
patient’s overall disease activity.
Safety, pharmacokinetic, and pharmacodynamic assess-
ments were done within 6 h and 2 h after each subcutaneous 
and intravenous dose administration, res pect ively. Any 
adverse events were documented through out the study 
at each treatment visit. Safety assess ments included 
physical examinations, electrocardio grams (ECGs), and 
stand ard clinical laboratory parameters such as haema-
tology, blood chemistry (blood alkaline phosphate, liver 
function tests, amylase, and lipase), com ple ment and B-cell 
hyper activity markers (levels of C3, C4, cryo globulin, free 
 immunoglobulin and  immuno globu lin light chains, 
and 2 microglobulin), urinalysis, and coagulation tests.
Exploratory outcomes included ESSDAI score, ESSPRI 
score, VAS, SF-36, and MFI, assessed at multiple time 
points, concentrations of anti-drug antibodies (before 
drug dosing, during treatment, and during follow-up), 
lacri mal gland function using Schirmer’s test (with -
 out anaes thesia), salivary function using salivary flow 
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(unstimu lated and stimulated), concentrations of serum 
auto antibodies, including rheumatoid factor, anti-nuclear 
antibodies, and anti-SSA and anti-SSB antibodies, and 
concentrations of soluble serum and salivary biomark -
ers, including BAFF, Eotaxin-1, Eotaxin-3, IP-10, MCP-1, 
MCP-4, MDC, MIP-1α, MIP-1, TARC, IL-8, I-TAC, 
CXCL-13, MCP-2, ENA-78, GRO alpha and MIP-3a, and 
structural changes of parotid salivary gland assessment 
by ultra sound. A full list of exploratory outcomes is 
included in the protocol. 
Statistical analysis
The planned sample size for cohort 1 was 12 patients on 
the basis of safety considerations. The planned sample 
size for cohort 2 was 30 patients based on the primary 
endpoint of ESSDAI (ie, only cohort 2 was fully powered 
for ESSDAI). The protocol prespecified that the primary 
endpoint for cohort 1 and cohort 2 would be considered 
to be achieved only if both of the follow ing conditions 
held for the reduction in ESSDAI after 12 weeks treatment 
in the iscalimab 10 mg/kg intravenous group (com-
pared with placebo): the reduction versus placebo was 
statistically significant at the one-sided 10% significance 
level and the reduction versus placebo was estimated to 
be at least 5 points in magnitude.
The one-sided 10% α level in the first condition was 
considered an appropriate upper bound for the false-
positive risk of an exploratory study. The second condition 
was included to ensure that the primary endpoint would 
only be considered achieved if the reduction was highly 
clinically relevant. The sample size of 30 patients in 
cohort 2 was chosen such that there was an 83% chance 
of achieving the primary endpoint (ie, meeting both 
these conditions), assuming a true reduction of 7 ESSDAI 
points compared with placebo, an SD of 5, and a dropout 
rate of 20%.
For clinical outcomes, we fitted mixed models for 
repeated measures with factors for treatment group, visit, 
baseline, and interaction between visit and treatment 
group. Where possible, an unstructured correlation matrix 
was assumed to account for correlation within patients. 
We fitted separate models for each of the cohorts. At each 
visit, the mean difference in outcome measure between 
iscalimab and placebo was calculated together with its 
95% CI. The same model was fitted to the log-transformed 
CXCL13 data. Analysis of covariance, adjusting for 
baseline levels, was done on week 12 salivary flow rate, 
Schirmer’s test, and auto-antibody measure ments. Auto-
antibody levels were log-transformed before analysis.
As per the analysis plan, all participants with a baseline 
ESSDAI and at least one post-baseline ESSDAI were 
included in the primary analysis and all participants who 
received at least one dose of the study drug were included 
in the safety analysis.
Statistical analyses were done with either SAS version 
9.4 or R version 3.4.3. The trial is registered with 
ClinicalTrials.gov, NCT02291029.
Role of the funding source
The funder of the study had a role in the study design, 
data analysis, data collection, data interpretation, and 
writing of the report. All authors had full access to all the 
data in the study and the corresponding author had final 
respons ibility for the decision to submit for publication.
Results
Between Oct 22, 2014, and June 28, 2016, we assessed 
82 patients for eligibility (25 for cohort 1 and 57 for 
cohort 2; figure 2). Cohort 1 took place between 
Oct 22, 2014, and June 15, 2016, and cohort 2 took place 
between Nov 16, 2015, and Feb 15, 2017. 38 patients were 
excluded because of ineligibility. In the double-blind 
period of cohort 1, 12 patients were randomly assigned to 
receive either 3 mg/kg doses of iscalimab (n=8) or placebo 
(n=4) via subcutaneous injections at weeks 0, 2, 4, and 8. 
In the double-blind period of cohort 2, 32 patients were 
randomly assigned to receive either intravenous 10 mg/kg 
doses of iscalimab (n=21) or placebo (n=11).
Two patients left the study because of an allergic 
reaction and skin rash (after completing treatment in the 
Figure 2: Trial profile
*Appeared eligible at screening visit and signed an informed consent form. However, during the 4-week screening 
period up to and including baseline they were found ineligible for randomisation for various reasons, such as 
meeting an exclusion criterion (eg, acute infection), not meeting all inclusion criteria (eg, disease activity no longer 
high enough), or withdrawel of informed consent. †Included in the primary analyses model but because of 
discontinuation only contributed data at the week 2 visit.
12 enrolled and randomised 
25 patients assessed for 
eligibility for cohort 1
1 discontinued 
due to 
allergy and 
skin rash 
8 assigned to 
iscalimab 3 mg/kg 
subcutaneous
4 assigned to 
matching placebo 
8 patients included 
in primary efficacy 
analysis
4 patients included 
in primary efficacy 
analysis
8 completed period 1 4 completed period 1 
8 completed period 2 3 completed period 2 
13 ineligible*  25 ineligible*  
32 enrolled and randomised 
57 patients assessed for 
eligibility for cohort 2
1 withdrew 
consent†
21 assigned to 
iscalimab 
10 mg/kg 
intravenous 
11 assigned to 
matching placebo 
20 included in 
primary efficacy 
analysis
11 included in 
primary efficacy 
analysis
20 completed 
period 1
11 completed 
period 1
20 completed 
period 2
11 completed 
period 2
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double-blind period of cohort 1) and one other withdrew 
consent (after two doses of study treatment in cohort 2; 
figure 2). Baseline characteristics of patients are shown 
in table 1.
In cohort 1, across the whole study period, all patients 
had at least one mild or moderate adverse event in both the 
iscalimab treatment group and placebo group (table 2). In 
cohort 2, across the whole study period, 11 (52%) patients 
had an adverse event in the iscalimab treatment group and 
seven (64%) did in the placebo group). In both cohorts, the 
most frequent adverse event was upper respiratory tract 
infection (cohort 1, two [25%] for iscalimab vs two [50%] for 
placebo; cohort 2, two [10%] for iscalimab vs two [18%]). We 
observed no major safety signals during the iscalimab 
treatment open-label period in both cohorts.
Although, we observed two serious adverse events 
(one case of bacterial con junctivitis in cohort 1 and one 
case of atrial fibrillation in cohort 2) during the safety 
follow-up period (around 12 weeks after the last dose of 
iscalimab) these were considered to be unrelated to study 
drug by the investigator. We found no clinic ally signifi-
cant abnormalities in laboratory assessments or ECG 
evaluations, and no B-cell or other cytopenia was noted, 
consistent with the non-depleting nature of iscalimab.16,21
We observed no improvement in ESSDAI in cohort 1, 
where the baseline-adjusted difference from placebo at 
week 12 was only 0·41 points (95% CI –2·89 to 3·70; 
figure 3). However, a reduction in disease activity 
compared with placebo did meet the prespecified criterion 
after four infusions of 10 mg/kg intravenous iscalimab 
in cohort 2, with a baseline-adjusted mean difference in 
ESSDAI at week 12 of 5·21 points (0·96 to 9·46; one-sided 
p=0·0090; figure 3; appendix p 5). A post-hoc analysis 
showed improvements in clinical ESSDAI (i.e. ESSDAI 
without the biological domain) at week 12 for cohort 2 
compared with placebo, with a reported reduction of 
6·10 points (1·08 to 11·11). ESSDAI domain results 
showed the most severely affected domain at baseline—
the articular domain—had the greatest reduction in 
ESSDAI score at week 12 (appendix p 2).
In cohort 1, iscalimab 3 mg/kg subcutaneous res-
ulted in mean trough plasma concentrations less than 
10 µg/mL (appendix p 1), substantially lower than expec-
ted based on pharma cokinetic data of healthy volunteers 
in the previous first-in-human study.22 In cohort 2 
(iscalimab 10 mg/kg intravenous), mean trough plasma 
concentrations were above the values previously rep-
orted to be suffici ent for the suppression of germinal 
centre develop ment and inhibition of T-cell-dependent 
antigen responses in non-human primates16 at around 
100–200 µg/mL (appendix p 1).
Target-mediated drug disposition of iscalimab is 
illustrated in the pharmacokinetic profiles from cohort 2. 
During the follow-up period, the inflection point in the 
pharmacokinetic profiles (at around 10–20 μg/mL) is a 
marker of target engagement and is associated with an 
Cohort 1 Cohort 2
Iscalimab 3 mg/kg 
subcutaneous (n=8)
Placebo then 
iscalimab 3 mg/kg 
subcutaneous (n=4)
Total (n=12) Iscalimab 10 mg/kg 
intravenous (n=21)
Placebo then 
iscalimab 10 mg/kg 
intravenous (n=11)
Total (n=32)
Age (years) 56·4  
(12·2; 34–72)
48·8  
(3·3; 45–52)
53·8  
(10·6; 34–72)
51·7  
(14·3; 24–72)
50·6  
(12·4; 25–69)
51·3  
(13·5; 24–72)
Sex
Male 0 0 0 2 (10%) 0 2 (6%)
Female 8 (100%) 4 (100%) 12 (100%) 19 (90%) 11 (100%) 30 (94%)
Weight (kg) 66·7  
(16·6; 50·0–91·1)
78·7  
(11·0; 64·1–89·1)
70·7  
(15·6; 50·0–91·1)
72·9  
(15·6; 50·0–107·2)
71·9  
(11·1; 52·8–92·0)
72·6  
(14·1; 50·0–107·2)
Baseline ESSDAI 12·0  
(3·8; 7–17)
11·8  
(3·9; 6–14)
11·9  
(3·6; 6–17)
10·6  
(4·4; 6–25)
11·0  
(5·2; 6–23)
10·7  
(4·6; 6–25)
Baseline ESSPRI 6·8  
(1·9; 4·0–10·0)
7·0  
(1·8; 5·0–9·0)
6·8  
(1·8; 4·0–10·0)
6·7  
(1·7; 2·3–9·7)
7·2  
(1·5; 3·7–9·0)
6·9  
(1·6; 2·3–9·7)
Antinuclear antibodies 8 (100%) 3 (75%) 11 (92%) 19 (90%) 9 (82%) 28 (88%)
Anti-SSA 7 (88%) 4 (100%) 11 (92%) 21 (100%) 11 (100%) 32 (100%)
Anti-SSB 7 (88%) 3 (75%) 10 (83%) 13 (62%) 8 (73%) 21 (66%)
Rheumatoid factor* 7 (88%) 2 (50%) 9 (75%) 16 (76%) 10 (91%) 26 (81%)
Concomitant medications
Antimalarials 1 (13%) 0 1 (8%) 7 (33%) 3 (27%) 10 (31%)
Azathioprine 0 0 0 1 (5%) 0 1 (3%)
Corticosteroids 0 0 0 8 (38%) 3 (27%) 11 (34%)
Methotrexate 0 0 0 2 (10%) 0 2 (6%)
Data are mean (SD; range) or n (%). EULAR=European League Against Rheumatism. ESSDAI=EULAR Sjögren’s syndrome disease activity index. ESSPRI=EULAR Sjogren’s 
Syndrome Patient Reported Index. SSA=Sjögren’s-syndrome-related antigen A. SSB=Sjögren’s-syndrome-related antigen B. *Patients with rheumatoid factor above normal.
Table 1: Baseline characteristics
See Online for appendix
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increased contribution of CD40 receptors to the overall 
clearance of iscalimab and faster elimination. This 
inflection point was associated with a loss of target 
engagement (total soluble CD40 profiles in plasma). In 
cohort 1, total soluble CD40 profiles in plasma showed 
a lack of sustained target engagement by iscalimab 
(appendix p 5).
ESSDAI improvements in the double-blind period of 
cohort 2 were sustained in the open-label period in patients 
who started on iscalimab (figure 3). For example, the 
reduction in ESSDAI at week 14 was 3·85 points (95% CI 
–0·43 to 8·12; one-sided p=0·038), at week 16 2·57 points 
(–0·51 to 5·66; one-sided p=0·049), and at week 20 
3·77 points (0·38 to 7·16; one-sided p=0·015) compared 
with the placebo group that switched to 10 mg/kg 
intravenous iscalimab after week 12. Improve ments were 
also observed in the placebo group after switching to 
10 mg/kg intravenous iscalimab at week 12 (figure 3).
In the placebo-controlled period of cohort 2, some 
improvements were observed in certain secondary out-
comes at week 12 . The mean decrease versus placebo in 
ESSPRI was 0·95 points (95% CI –0·50 to 2·41; figure 3). 
For SF-36, the mean increases versus placebo in the 
physical and mental component scores were 3·83 points 
(–1·81 to 9·48) and 2·52 points (–4·50 to 9·53), 
respectively. For total MFI, the mean reduction versus 
placebo was 9·83 points (–1·01 to 20·66). For patient 
assess ments and investigator assesments using VAS, the 
mean decreases were 8·14 points (–10·39 to 26·67) and 
12·16 points (2·38 to 21·94), respectively (appendix p 3).
Improvements were observed in patients in the 
10 mg/kg intravenous iscalimab group compared with 
the placebo group in unstimulated and stimulated salivary 
flow and in Schirmer’s test. The mean increase versus 
placebo in unstimulated salivary flow at week 12 was 
0·04 mL/min (95% CI –0·03 to 0·10), in stimulated flow it 
Cohort 1 Cohort 2
Iscalimab 3 mg/kg 
subcutaneous (n=8)
Placebo then 
iscalimab 3 mg/kg 
subcutaneous (n=4)
Total (n=12) Iscalimab 10 mg/kg 
intravenous (n=21)
Placebo then 
iscalimab 10 mg/kg 
intravenous (n=11)
Total (n=32)
Placebo-controlled first treatment period*
Patients with adverse events 34; 7 (88%) 17; 4 (100%) 51; 11 (92%) 23; 7 (33%) 14; 6 (55%) 37; 13 (41%)
Adverse events of mild intensity 29; 6 (75%) 14; 3 (75%) 43; 9 (75%) 16; 7 (33%) 10; 4 (36%) 26; 11 (34%)
Adverse events of moderate 
intensity
5; 3 (38%) 2; 1 (25%) 7; 4 (33%) 7; 4 (19%) 4; 4 (36%) 11; 8 (25%)
Adverse events of severe intensity 0 1; 1 (25%) 1; 1 (8%) 0 0 0
Study drug-related AEs 11; 3 (38%) 0 11; 3 (25%) 0 2; 1 (9%) 2; 1 (3%)
Most frequent adverse events during the clinical trial†
Patients with adverse events 8 (100%) 4 (100%) 12 (100%) 11 (52%) 7 (64%) 18 (56%)
Upper respiratory tract infection 2 (25%) 2 (50%) 4 (33%) 2 (10%) 2 (18%) 4 (13%)
Headache 0 1 (25%) 1 (8%) 2 (10%) 1 (9%) 3 (9%)
Nasopharyngitis 0 0 0 0 2 (18%) 2 (6%)
Arthralgia 2 (25%) 1 (25%) 3 (25%) 0 1 (9%) 1 (3%)
Diarrhoea 1 (13%) 1 (25%) 2 (17%) 2 (10%) 1 (9%) 3 (9%)
Rash 2 (25%) 1 (25%) 3 (25%) 1 (5%) 1 (9%) 2 (6%)
Dizziness 2 (25%) 1 (25%) 3 (25%) 1 (5%) 0 1 (3%)
Lower respiratory tract infection 2 (25%) 1 (25%) 3 (25%) 0 0 0
Urinary tract infection 2 (25%) 0 2 (17%) 0 0 0
Nausea 1 (13%) 1 (25%) 2 (17%) 1 (5%) 0 1 (3%)
Toothache 1 (13%) 1 (25%) 2 (17%) 1 (5%) 0 1 (3%)
Vomiting 2 (25%) 0 2 (17%) 1 (5%) 0 1 (3%)
Contusion 0 0 0 2 (10%) 1 (9%) 3 (9%)
Bronchitis 0 0 0 0 1 (9%) 1 (3%)
Constipation 0 0 0 0 1 (9%) 1 (3%)
Iron deficiency anaemia 0 0 0 1 (5%) 1 (9%) 2 (6%)
Lipase increased 0 0 0 0 2 (18%) 2 (6%)
Photosensitivity reaction 0 0 0 1 (5%) 1 (9%) 2 (6%)
Data are number of adverse events; number of patients with at least one adverse event (%) or number of patients (%). In the list of most frequent adverse events, only events 
that occurred in more than one patient within at least one cohort are reported. *During the placebo controlled first treatment period no serious adverse events, adverse 
events leading to discontinuation of study treatment, or study-drug related adverse events leading to discontinuation of study treatment occurred. †None of the following 
adverse events were reported: dehydration, dyspepsia, injection site haematoma, oral herpes, and peripheral swelling.
Table 2: Summary of overall incidence and severity of adverse events in the placebo-controlled first treatment period and the most frequent adverse 
events during the trial
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was 0·16 mL/min (–0·15 to 0·46), and for Schirmer’s test 
it was 8·06 mm (–1·37 to 17·50) for the left eye and 
9·07 mm (–4·61 to 22·75) for the right eye (appendix p 3).
Expression of exploratory biomarkers other than 
CXCL13 showed no relevant changes but will be reported 
in full elsewhere. Decreases in CXCL13 serum conce-
ntrations after 10 mg/kg intravenous iscalimab compared 
with placebo in cohort 2 (56% reduction in geometric 
mean vs placebo at week 12, 95% CI 27–70; figure 3) 
were similar to the changes in ESSDAI (figure 3). The 
maximum decreases in CXCL13 were reached at week 8 
(61% reduction vs placebo) and were sustained until 
week 24 (31% reduction vs placebo). In patients who were 
switched to iscalimab from placebo at week 12, CXCL13 
serum concentrations decreased between weeks 12 and 
16, and slightly increased thereafter, up to week 24 
(figure 3). 
Levels of anti-SSA 52, anti-SSA 60, and anti-SSB IgG 
were elevated at baseline as expected for primary Sjögren’s 
syndrome.2 A modest decrease from baseline in anti-
SSA 52 IgG was observed after four doses of 10 mg/kg 
intravenous iscalimab at week 12, but a similar decrease 
was observed in patients in the placebo group. Although 
decreases from baseline in serum proportions of anti-
SSA 60 and anti-SSB IgG after 12 weeks of treatment with 
iscalimab (10 mg/kg intravenous) were more pronounced 
compared with placebo, they were not significant (anti-
SSA: 20% reduct ion vs placebo, 95% CI 17–45; anti-SSB: 
38% reduction vs placebo, 19–68%; appendix p 4).
In cohort 1, we observed no consistent change from 
screening in the blood concentrations of rheumatoid 
factor in the iscalimab and placebo groups. In patients 
in the iscalimab group in cohort 2, rheumatoid factor 
decreased from a median of 22·7 U/mL (IQR 14·7–70·6) 
at screening to 15·3 U/mL (8·5–51·9) at week 12. 
In the placebo group, the median decreased from 
27·1 U/mL (15·5–90·6) to 20·6 U/mL (17·2–76·6). 
Antinuclear antibody titres decreased from a median of 
640 (IQR 160–1280) at screening to 320 (80–1280) at 
week 12 in the iscalimab group. Median titres in the 
placebo group also decreased from 640 (80–1280) at 
screening to 240 (80–640) at week 12.
In the standard assays reflecting complement and B-cell 
hyperactivity, including levels of C3, C4, cryoglobulin, free 
λ immunoglobulin and λ immunoglobulin light chains, 
Figure 3: Baseline-adjusted mean ESSDAI (A), ESSPRI (B) and CXCL13 (C) 
levels after administration of different doses of iscalimab or placebo
Mean estimates from the mixed models for repeated measures adjusting for 
baseline levels (ie, baseline-adjusted means) are presented along with associated 
SEs (error bars). The dashed blue line indicates the mean estimate for patients 
who were randomly assigned to the placebo group but, in the open label part of 
the study, received iscalimab 3 mg/kg subcutaneous in cohort 1 or 10 mg/kg 
intravenous in cohort 2. EULAR=European League Against Rheumatism. 
ESSDAI=EULAR Sjögren’s syndrome disease activity index. ESSPRI=EULAR 
Sjogren’s Syndrome Patient Reported Index.
Placebo
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and 2 micro globulin, we observed no clinically meaning-
ful changes after 12 weeks of treatment compared with 
placebo (data not shown).
During immunogenicity testing, one sample (at day 
225; a patient in cohort 1 treated with iscalimab in the 
open-label period) was confirmed positive for anti-drug 
antibody. The presence of anti-drug antibody was not 
associated with any immune-related safety signals.
In a post-hoc analysis of cohort 2, the percentages of 
ESSDAI and ESSPRI responders at week 12 were higher 
in the iscalimab group than in the placebo group. For 
ESSDAI, 16 (76%) of 21 patients in the iscalimab group 
achieved a 3 point or more reduction compared with 
6 (55%) of 11 patients in the placebo group. 13 (62%) of 
21 patients in the iscalimab group reduced their ESSDAI 
to below 5 points compared with four (36%) of 11 in the 
placebo group. For ESSPRI, 13 (62%) of 21 patients in 
the iscalimab group achieved a 1 point or more reduction 
compared with 5 (45%) of 11 in the placebo group 
(appendix p 6).
Discussion
To date, a small number of randomised trials have 
examined the effects of different treatments in primary 
Sjögren’s syndrome, with none of these showing convinc-
ing clinical efficacy.23,24 Our proof-of-concept study assessed 
the CD40 blocking antibody iscalimab and, for the first 
time to our knowledge, showed clinically meaningful 
improvements in ESSDAI when compared with placebo.
Iscalimab 10 mg/kg intravenous results in a clinically 
mean ingful reduction in disease activity (measured by 
ESSDAI) after 12 weeks in patients in the iscalimab 
group compared with patients in the placebo group. 
The continued reductions we observed in ESSDAI after 
week 12 through to week 32 and the reduction in ESSDAI 
observed in the placebo group once patients were switched 
to active treatment at week 12 suggest iscalimab efficacy 
in the treatment of patients with primary Sjögren’s 
syndrome. The articular domain of ESSDAI showed the 
greatest improvement but also was the most severely 
affected at baseline. This finding warrants further study of 
tender and swollen joint counts and the disease activity 
score using 28 joint counts to understand the importance 
of this domain in driving ESSDAI improvements.
The lower than expected iscalimab plasma concentrations 
in cohort 1 could be the consequence of efficient target-
mediated drug disposition of iscalimab and first-pass effect. 
The disposition of iscalimab depends on its plasma 
concentration, interstitial fluid, and lymph circulation, 
along with CD40 receptor expression, internalisation, and 
turnover. When CD40 receptors are fully satu rated, target-
mediated drug disposition becomes saturated and the 
contribution of CD40 receptors to the overall clear ance 
of iscalimab is small. In cohort 1, the dosing regimen 
generated non-saturating conditions, and CD40-mediated 
clearance was efficient and associated with rapid elimina-
tion of iscalimab.
As CD40 receptors have been reported to be upregulated 
on parenchyma in inflamed tissues, elevated expression 
of CD40 receptors in primary Sjögren’s syndrome is 
probably responsible for the rapid elimination and 
efficient first-pass effect after 3 mg/kg subcutaneous 
iscalimab. This underlying explanation is further sug-
gested by improve ments in ESSDAI in cohort 2, where 
trough plasma concentrations were above 100 µg/mL, 
suggesting a dose–response relationship for iscalimab 
that supports the dose-dependent pharmacology observed 
in non-human primates.16,25
Importantly, iscalimab was well-tolerated and the 
number of adverse events in both cohorts was similar to 
placebo. Furthermore, we found no evidence of cyto-
penias, injection site reactions, thromboembolic events, 
or increased risk for infections, which have previously 
been observed with biologicals targeting CD154.26
The clinical efficacy observed of iscalimab suggests 
that CD40–CD154 signalling is a key pathway associated 
with the underlying pathology of primary Sjögren’s 
syndrome. Our 2019 study in a mouse model of primary 
Sjögren’s syndrome15 suggested that iscalimab acts by 
several diff erent mech anisms, including the suppression 
of ectopic lymphoic structure formation and function 
by inhib i tion of CD40–CD154 interactions in salivary 
glands, the inhibition of sialadenitis, and reduction of 
B-cell hyperreactivity. The germinal centre-associated 
chemo kine CXCL13 has previously been shown to be 
elevated in the serum of some patients with primary 
Sjögren’s syndrome6,27 and is expressed by infiltrating 
cells in salivary gland tissue.28 When serum CXCL13 
concentrations from patients in this study were compared 
with those in healthy volunteers from a previous study, 
levels were elevated at baseline in some individuals 
but returned to a range similar to that seen in untreated 
healthy volunteers after treatment with 10 mg/kg 
intravenous iscalimab.29
Published data on CXCL13 suggest that it could 
be a biomarker that reflects germinal centre activity 
and correlates with the extent of salivary gland pathol-
ogy.7 Therefore, the iscalimab-dependent reductions in 
CXCL13 that preceded clinical improvement might reflect 
sup pression of the structure and function of germinal 
centres and possibly salivary gland ectopic lymphoid 
structures. Given that the individuals in this study also 
had extraglandular involvement based on their ESSDAI 
scores of 6 or greater, the clinical benefit observed with 
iscalimab might also extend to extraglandular tissues.
By contrast with the substantial reductions in CXCL13, 
we observed no or modest reductions in primary Sjögren’s 
syndrome-associated IgG autoantibodies in patients treated 
with iscalimab. This finding suggests that CD40–CD154 
blockade might be less effective in reducing anti body 
production from long-lived plasma cells, a hypothesis 
consistent with the observation of unaffected serum 
immuno globulin concentrations in preclinical and clini -
cal studies with iscalimab.16,17 However, SSA and SSB 
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antibodies are diagnostic markers of the disease rather 
than pathogenic factors.
Although the B-cell depleting agent rituximab has been 
used in selected primary Sjögren’s syndrome cases, 
previous clinical studies have reported variable therapeutic 
benefit.30 Therefore, CD40 blockade with iscalimab could 
have additional effects beyond targeting B-cell hyper-
reactivity in primary Sjögren’s syndrome, possibly due 
to involvement of CD40-expressing non-B cell types 
in prim ary Sjögren’s syndrome pathology, including 
macro phages and other antigen-presenting cells, such as 
dendritic cells. This hypothesis was also supported by 
2019 data in the non-obese diabetic mouse model of 
Sjögren’s syndrome showing a reduction in macrophages 
following therapeutic blockade of CD40–CD154.15 Addi-
tion ally, iscalimab might be more effective at suppressing 
the effector functions of pathogenic B cells in tissue than 
depleting B cells.
Our study was designed as an exploratory phase 2a trial 
to provide initial safety and proof-of-concept for iscalimab 
in patients with primary Sjögren’s syndrome. However, 
the study has limitations, including the small sample 
size and the short duration of the trial, and many of the 
improvements seen in the clinical outcomes did not 
reach statistical significance. Furthermore, our results on 
the ESSDAI domain do not allow firm conclusions 
because of the lack of baseline activity for many domains.
In conclusion, the results of this exploratory clinical 
trial suggest a pivotal role of CD40–CD154 interactions in 
primary Sjögren’s syndrome pathology. Further studies 
are warranted with larger sample sizes and longer dura-
tions to assess whether CD40 blockade with iscalimab 
might result in clinically meaningful benefit in patients 
with primary Sjögren’s syndrome.
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